328 related articles for article (PubMed ID: 29748761)
1. Gene expression in triple-negative breast cancer in relation to survival.
Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
[TBL] [Abstract][Full Text] [Related]
2. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
[TBL] [Abstract][Full Text] [Related]
3. SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer.
Zhu A; Yuan P; Du F; Hong R; Ding X; Shi X; Fan Y; Wang J; Luo Y; Ma F; Zhang P; Li Q; Xu B
Oncotarget; 2016 Nov; 7(47):76628-76634. PubMed ID: 27421134
[TBL] [Abstract][Full Text] [Related]
4. CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
Pedersen MH; Hood BL; Ehmsen S; Beck HC; Conrads TP; Bak M; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2019 Feb; 144(3):631-640. PubMed ID: 30110125
[TBL] [Abstract][Full Text] [Related]
5. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
6. ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer.
Liu Y; Baglia M; Zheng Y; Blot W; Bao PP; Cai H; Nechuta S; Zheng W; Cai Q; Shu XO
Oncotarget; 2015 Dec; 6(38):41360-9. PubMed ID: 26462023
[TBL] [Abstract][Full Text] [Related]
7. High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.
Na H; Han J; Ka NL; Lee MH; Choi YL; Shin YK; Lee MO
Breast Cancer Res; 2019 Nov; 21(1):127. PubMed ID: 31779659
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients.
Gong W; Liu Y; Preis S; Geng X; Petit-Courty A; Kiechle M; Muckenhuber A; Dreyer T; Dorn J; Courty Y; Magdolen V
Mol Med; 2020 Feb; 26(1):19. PubMed ID: 32028882
[TBL] [Abstract][Full Text] [Related]
9. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
[TBL] [Abstract][Full Text] [Related]
10. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
11. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ; Lambe SM; Badve S; Gökmen-Polar Y; Pathak HB; Isakova K; Linden HM; Porter P; Pusztai L; Thompson AM; Tripathy D; Hortobagyi GN; Hayes DF
J Clin Oncol; 2019 Dec; 37(36):3484-3492. PubMed ID: 31657982
[TBL] [Abstract][Full Text] [Related]
12. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
13. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
Wu W; Wu M; Peng G; Shi D; Zhang J
Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
[TBL] [Abstract][Full Text] [Related]
14. Subcellular expression of MTA1, HIF1A and p53 in primary tumor predicts aggressive triple negative breast cancers: a meta-analysis based study.
Sharaf SS; Jaganath Krishna KM; Lekshmi A; Sujathan
J Mol Histol; 2024 Jun; 55(3):303-315. PubMed ID: 38613589
[TBL] [Abstract][Full Text] [Related]
15. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
Yeong J; Lim JCT; Lee B; Li H; Ong CCH; Thike AA; Yeap WH; Yang Y; Lim AYH; Tay TKY; Liu J; Wong SC; Chen J; Lim EH; Iqbal J; Dent R; Newell EW; Tan PH
J Immunother Cancer; 2019 Feb; 7(1):34. PubMed ID: 30728081
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of ERBB4 expression in patients with triple negative breast cancer.
Kim JY; Jung HH; Do IG; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Park YH; Im YH
BMC Cancer; 2016 Feb; 16():138. PubMed ID: 26907936
[TBL] [Abstract][Full Text] [Related]
19. Prediction of prognostic signatures in triple-negative breast cancer based on the differential expression analysis via NanoString nCounter immune panel.
Lim GB; Kim YA; Seo JH; Lee HJ; Gong G; Park SH
BMC Cancer; 2020 Nov; 20(1):1052. PubMed ID: 33138797
[TBL] [Abstract][Full Text] [Related]
20. Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.
Siddappa CM; Pillai SG; Snider J; Alldredge P; Trinkaus K; Watson MA; Aft R
Breast Cancer Res Treat; 2019 Nov; 178(2):317-325. PubMed ID: 31432366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
